SE8902638L - Stabiliserade protein- eller peptidkonjugat - Google Patents

Stabiliserade protein- eller peptidkonjugat

Info

Publication number
SE8902638L
SE8902638L SE8902638A SE8902638A SE8902638L SE 8902638 L SE8902638 L SE 8902638L SE 8902638 A SE8902638 A SE 8902638A SE 8902638 A SE8902638 A SE 8902638A SE 8902638 L SE8902638 L SE 8902638L
Authority
SE
Sweden
Prior art keywords
protein
peptide
peptide conjugate
vivo
binding
Prior art date
Application number
SE8902638A
Other languages
Unknown language ( )
English (en)
Other versions
SE509359C2 (sv
SE8902638D0 (sv
Inventor
P-Aa Nygren
Original Assignee
Cemu Bioteknik Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cemu Bioteknik Ab filed Critical Cemu Bioteknik Ab
Priority to SE8902638A priority Critical patent/SE509359C2/sv
Publication of SE8902638D0 publication Critical patent/SE8902638D0/sv
Priority to AU61439/90A priority patent/AU652124B2/en
Priority to DE69010206T priority patent/DE69010206T2/de
Priority to AT90911434T priority patent/ATE107514T1/de
Priority to JP51095890A priority patent/JP3477196B2/ja
Priority to EP90911434A priority patent/EP0486525B1/en
Priority to PCT/SE1990/000509 priority patent/WO1991001743A1/en
Priority to CA002064689A priority patent/CA2064689C/en
Publication of SE8902638L publication Critical patent/SE8902638L/sv
Priority to US08/162,906 priority patent/US6267964B1/en
Publication of SE509359C2 publication Critical patent/SE509359C2/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE8902638A 1989-08-01 1989-08-01 Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel SE509359C2 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE8902638A SE509359C2 (sv) 1989-08-01 1989-08-01 Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
CA002064689A CA2064689C (en) 1989-08-01 1990-07-31 Stabilized protein or peptide conjugates
JP51095890A JP3477196B2 (ja) 1989-08-01 1990-07-31 安定化されたタンパク質またはペプチド接合体
DE69010206T DE69010206T2 (de) 1989-08-01 1990-07-31 Stabilisierte protein- oder peptidkonjugate.
AT90911434T ATE107514T1 (de) 1989-08-01 1990-07-31 Stabilisierte protein- oder peptidkonjugate.
AU61439/90A AU652124B2 (en) 1989-08-01 1990-07-31 Stabilized protein or peptide conjugates
EP90911434A EP0486525B1 (en) 1989-08-01 1990-07-31 Stabilized protein or peptide conjugates
PCT/SE1990/000509 WO1991001743A1 (en) 1989-08-01 1990-07-31 Stabilized protein or peptide conjugates
US08/162,906 US6267964B1 (en) 1989-08-01 1993-12-08 Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8902638A SE509359C2 (sv) 1989-08-01 1989-08-01 Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel

Publications (3)

Publication Number Publication Date
SE8902638D0 SE8902638D0 (sv) 1989-08-01
SE8902638L true SE8902638L (sv) 1991-02-02
SE509359C2 SE509359C2 (sv) 1999-01-18

Family

ID=20376608

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8902638A SE509359C2 (sv) 1989-08-01 1989-08-01 Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel

Country Status (8)

Country Link
EP (1) EP0486525B1 (sv)
JP (1) JP3477196B2 (sv)
AT (1) ATE107514T1 (sv)
AU (1) AU652124B2 (sv)
CA (1) CA2064689C (sv)
DE (1) DE69010206T2 (sv)
SE (1) SE509359C2 (sv)
WO (1) WO1991001743A1 (sv)

Families Citing this family (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
EP0802798A1 (en) * 1994-02-23 1997-10-29 Chiron Corporation Method and compositions for increasing the serum half-life of pharmacologically active agents
FR2726471B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
EP1619250B1 (en) * 1996-01-08 2009-11-25 Genentech, Inc. OB receptor variant and ligands
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
CA2330611A1 (en) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
WO2000022112A1 (en) 1998-10-13 2000-04-20 The University Of Georgia Research Foundation, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
WO2001035748A1 (en) * 1999-11-19 2001-05-25 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules having modulated pharmacokinetic properties and therapies based thereon
EP1229924A4 (en) 1999-11-19 2004-12-15 Univ Leland Stanford Junior TARGETED BIFUNCTIONAL MOLECULES AND THERAPIES THEREFORE
EP1757311B1 (en) 1999-12-24 2009-02-11 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
JP2003518075A (ja) * 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
WO2004003019A2 (en) * 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
EP1536818A2 (en) 2002-03-26 2005-06-08 Dyax Corp. Fibrinogen binding moieties
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
DE05733048T1 (de) * 2004-04-06 2007-05-10 Affibody Ab Serumalbuminbindende peptidkonjugate zur arzneimittelherstellung
KR20120133403A (ko) * 2004-06-01 2012-12-10 도만티스 리미티드 증강된 혈청 반감기를 가지는 이특이성 융합 항체
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
KR20070073886A (ko) * 2004-10-05 2007-07-10 제넨테크, 인크. 독성이 감소된 치료제
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
CA2589802A1 (en) * 2004-12-02 2006-06-08 Domantis Limited Plad domain peptides with increased serum half life due to conjugation to domain antibodies
CA2588892A1 (en) * 2004-12-02 2006-06-08 Dormantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
EP1888640B1 (en) 2005-05-18 2012-03-14 Ablynx N.V. Improved nanobodies against tumor necrosis factor-alpha
EP1940880A2 (en) * 2005-10-14 2008-07-09 Novo Nordisk A/S Treating diabetes using inhibitors of il-1
ATE536369T1 (de) * 2006-10-11 2011-12-15 Ablynx Nv Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2557090A3 (en) 2006-12-19 2013-05-29 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
AU2008281913B2 (en) 2007-07-31 2013-11-07 Affibody Ab New albumin binding compositions, methods and uses
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
WO2009068630A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
WO2009124931A2 (en) 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
DK2285408T3 (en) 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
DK2334705T3 (en) 2008-09-26 2017-03-27 Ucb Biopharma Sprl BIOLOGICAL PRODUCTS
WO2010056550A1 (en) 2008-10-29 2010-05-20 Wyeth Llc Methods for purification of single domain antigen binding molecules
CN102271707B (zh) 2008-10-29 2015-04-08 阿布林克斯公司 单域抗原结合性分子的制剂
US9260508B2 (en) 2008-12-19 2016-02-16 Ablynx N.V. Method for generation of immunoglobulin sequences
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
US8748581B2 (en) 2009-04-10 2014-06-10 Ablynx N.V. Anti-IL-6R polypeptides and pharmaceutical compositions thereof
BRPI1016055A2 (pt) 2009-04-27 2016-05-10 Novartis Ag composição e métodos de uso para anticorpos terapêuticos específicos para a subunidade beta i do receptor de il-12
SI2424895T1 (en) 2009-04-27 2018-01-31 Novartis Ag Ingredients and procedures for increasing muscle growth
SG176095A1 (en) 2009-06-05 2011-12-29 Ablynx Nv Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
WO2011056124A1 (en) 2009-11-04 2011-05-12 Affibody Ab Her3 binding polypeptides
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP2513145B1 (en) 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
KR20120107122A (ko) 2009-12-22 2012-09-28 노파르티스 아게 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
KR20130093470A (ko) * 2010-04-30 2013-08-22 가부시키가이샤산와카가쿠켄큐쇼 생리활성 물질 등의 생체 내 안정성 향상을 위한 펩티드 및 생체 내 안정성이 향상된 생리활성 물질
EP3546483A1 (en) 2010-05-20 2019-10-02 Ablynx N.V. Biological materials related to her3
JP5827994B2 (ja) 2010-07-09 2015-12-02 アフィボディ・アーベー ポリペプチド
CN103370083B (zh) 2010-09-28 2016-11-16 艾米琳制药有限责任公司 具有增强的作用持续时间的工程化多肽
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
CN103154037A (zh) 2010-10-05 2013-06-12 诺瓦提斯公司 抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
EP2638068B1 (en) 2010-11-08 2018-12-26 Novartis AG Cxcr2 binding polypeptides
ES2758352T3 (es) 2010-11-26 2020-05-05 Molecular Partners Ag Proteínas de repetición diseñadas que se une a la seroalbúmina
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
EP2691418A1 (en) 2011-03-28 2014-02-05 Ablynx N.V. Bispecific anti-cxcr7 immunoglobulin single variable domains
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2707391B1 (en) 2011-05-13 2017-11-08 Gamamabs Pharma Antibodies against her3
CN108329391A (zh) 2011-05-27 2018-07-27 埃博灵克斯股份有限公司 使用rankl结合肽抑制骨质吸收
JP2014519338A (ja) 2011-06-16 2014-08-14 ノバルティス アーゲー 治療薬として使用される可溶性タンパク質
RU2014101707A (ru) 2011-06-22 2015-07-27 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
EP2723376B1 (en) 2011-06-22 2018-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． ＩｇＥに対する免疫グロブリン単一可変ドメイン
HUE040276T2 (hu) 2011-07-01 2019-02-28 Novartis Ag Eljárás metabolikus rendellenességek kezelésére
EP2747782B1 (en) 2011-09-23 2018-01-17 Ablynx NV Prolonged inhibition of interleukin-6 mediated signaling
SG10201504605RA (en) 2011-09-23 2015-07-30 Technophage Investigação E Desenvolvimento Em Biotecnologia Sa Anti-Tumor Necrosis Factor-Alpha Agents And Uses Thereof
CA2849705A1 (en) 2011-09-23 2013-03-28 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Modified albumin-binding domains and uses thereof to improve pharmacokinetics
EP2747783B1 (en) 2011-09-30 2017-06-14 Ablynx N.V. Biological materials related to c-met
CA2856216C (en) 2011-11-11 2021-01-12 Ucb Pharma S.A. Albumin binding antibodies and binding fragments thereof
WO2013126006A1 (en) 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
WO2013143890A1 (en) 2012-03-28 2013-10-03 Affibody Ab Oral administration
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
MX349035B (es) 2012-05-17 2017-07-07 Extend Biosciences Inc Portadores para el suministro mejorado de farmaco.
JP6590695B2 (ja) 2012-09-25 2019-10-16 アフィボディ・アーベー アルブミン結合ポリペプチド
WO2014053586A1 (en) 2012-10-05 2014-04-10 Affibody Ab Her3 binding polypeptides
PL2912054T3 (pl) 2012-10-25 2017-11-30 Affibody Ab Polipeptyd wiążący albuminę
JP6396303B2 (ja) 2012-10-25 2018-09-26 アフィボディ・アーベー アルブミン結合を含有するタンパク質の分離方法
WO2014076179A1 (en) 2012-11-14 2014-05-22 Affibody Ab New polypeptide
EP2752426A1 (en) 2013-01-03 2014-07-09 Covagen AG Human serum albumin binding compounds and fusion proteins thereof
WO2015198217A2 (en) 2013-02-08 2015-12-30 Novartis Ag Compositions and methods for long-acting antibodies targeting il-17
CA3185317A1 (en) 2013-02-08 2014-08-14 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
WO2014210029A1 (en) 2013-06-24 2014-12-31 Riogin Corporation Double binding constructs
RU2016108652A (ru) 2013-08-14 2017-09-14 Новартис Аг Способы лечения спорадического миозита с тельцами включений
TR201911279T4 (tr) 2013-08-28 2019-08-21 Affibody Ab Mutasyona uğramış bir yapı iskelesine sahip polipeptidlerin bağlanması.
WO2015028558A1 (en) 2013-08-28 2015-03-05 Swedish Orphan Biovitrum Ab (Publ) Stable polypeptides binding to human complement c5
US10196455B2 (en) 2013-11-07 2019-02-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neuregulin allosteric anti-HER3 antibody
WO2015091957A1 (en) 2013-12-20 2015-06-25 Affibody Ab Engineered albumin binding polypeptide
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
EP3227319B1 (en) * 2014-12-04 2019-11-27 Novartis AG Methods and compositions using klotho variant polypeptides
WO2016100803A2 (en) 2014-12-19 2016-06-23 Alexion Pharmaceuticals, Inc. Methods of treating tissue calcification
BR112017020986A2 (pt) 2015-04-02 2018-08-14 Molecular Partners Ag. proteínas de ligação recombinantes e seu uso
AU2016239844B2 (en) 2015-04-02 2021-05-13 Ablynx N.V. Bispecific CXCR4-CD-4 polypeptides with potent anti-HIV activity
RS59376B1 (sr) 2015-05-13 2019-11-29 Ablynx Nv Polipeptidi koji regrutuju t-ćelije na bazi tcr-alfa/beta reaktivnosti
EP3294319B1 (en) 2015-05-13 2024-04-24 Ablynx NV T cell recruiting polypeptides based on cd3 reactivity
US10526415B2 (en) 2015-05-22 2020-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the Cath-D catalytic activity and its binding to the LRP1 receptor
JP6983075B2 (ja) 2015-06-02 2021-12-17 ノヴォ ノルディスク アー／エス 極性の組換え延長部を有するインスリン
JP2018528763A (ja) 2015-07-31 2018-10-04 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルムの除去のためのペプチドおよび抗体
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
KR20180092947A (ko) 2015-10-30 2018-08-20 더 리전츠 오브 더 유니버시티 오브 캘리포니아 형질 전환 성장 인자-베타-반응성 폴리펩티드 및 이의 사용 방법
RU2018122255A (ru) 2015-11-27 2019-12-19 Аблинкс Нв Полипептиды, ингибирующие cd40l
US11364284B2 (en) 2016-06-16 2022-06-21 Inozyme Pharma, Inc. Methods of treating myointimal proliferation
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
BR112019001693A2 (pt) 2016-07-29 2019-07-02 Ct Hospitalier Universitaire Toulouse anticorpos direcionados a macrófagos associados a tumores e seus usos
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
EP3512880A1 (en) 2016-09-15 2019-07-24 Ablynx NV Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
US10717772B2 (en) 2016-09-22 2020-07-21 Molecular Partners Ag Recombinant binding proteins targeting HER2 and serum albumin, and their uses
CA3043515A1 (en) 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
WO2018129078A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
AU2018206560A1 (en) 2017-01-04 2019-07-18 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
CN110392697A (zh) 2017-03-02 2019-10-29 国家医疗保健研究所 对nectin-4具有特异性的抗体及其用途
JP2020513808A (ja) 2017-03-15 2020-05-21 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法
CN110461359A (zh) 2017-03-24 2019-11-15 诺华股份有限公司 用于预防和治疗心脏病的方法
WO2018185131A2 (en) 2017-04-05 2018-10-11 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
EP3630818A1 (en) 2017-06-02 2020-04-08 Ablynx NV Aggrecan binding immunoglobulins
MX2019014400A (es) 2017-06-02 2020-02-10 Merck Patent Gmbh Inmunoglobulinas que se unen a adamts.
CA3064469A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Mmp13 binding immunoglobulins
MX2019014397A (es) 2017-06-02 2020-02-10 Merck Patent Gmbh Polipeptidos que enlazan adamts5, mmp13 y agrecano.
US20200181271A1 (en) 2017-06-28 2020-06-11 Novartis Ag Methods for preventing and treating urinary incontinence
CN117327187A (zh) 2017-07-11 2024-01-02 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
CA3096821A1 (en) 2017-09-27 2019-04-04 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
CA3075969A1 (en) 2017-10-10 2019-04-18 Numab Therapeutics AG Multispecific antibody
EP3552631A1 (en) 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
CA3100007A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
JP2021523741A (ja) 2018-05-14 2021-09-09 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なインターロイキン１２ポリペプチド及びその使用方法
CN113286819A (zh) 2018-08-01 2021-08-20 感应检查疗法公司 抗btn3a抗体及其在治疗癌症或感染性病症中的用途
EP3849602A1 (en) 2018-09-10 2021-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of her2/neu antibody with heme for treating cancer
MX2021003543A (es) 2018-09-27 2021-06-23 Xilio Dev Inc Polipeptidos de citocinas enmascaradas.
US20210338783A1 (en) 2018-10-05 2021-11-04 Research Institute At Nationwide Children's Hospital Compositions and methods for enzymatic disruption of bacterial biofilms
EP3947446A1 (en) 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
SG11202112541RA (en) 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
EA202193345A1 (ru) 2019-06-12 2022-03-16 Новартис Аг Антитела к рецептору-1 натрийуретического пептида и способы их применения
AU2020311897A1 (en) 2019-07-08 2022-02-03 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
CN114391024A (zh) 2019-09-02 2022-04-22 生物测试股份公司 具有增加的半衰期的因子viii蛋白
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
EP4034560A1 (en) 2019-09-27 2022-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance antibodies and uses thereof
TW202128160A (zh) 2019-10-18 2021-08-01 美國加利福尼亞大學董事會 用於治療病原性血管病症之方法及組合物
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
EP4072682A1 (en) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Antibodies having specificity to her4 and uses thereof
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
AU2021205639A1 (en) 2020-01-10 2022-07-14 Centre National De La Recherche Scientifique - Cnrs - Rspo1 proteins and their use
US20230190881A1 (en) 2020-02-17 2023-06-22 Biotest Ag Subcutaneous administration of factor viii
EP4149558A1 (en) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
EP3915580A1 (en) 2020-05-29 2021-12-01 Numab Therapeutics AG Multispecific antibody
US20230265211A1 (en) 2020-06-29 2023-08-24 Inserm (Institut National De La Santé Et De Ls Recherche Médicale) Anti-protein s single-domain antibodies and polypeptides comprising thereof
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
PE20231953A1 (es) 2020-12-07 2023-12-06 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos
WO2022130182A1 (en) 2020-12-14 2022-06-23 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
EP4288451A1 (en) 2021-02-02 2023-12-13 Numab Therapeutics AG Multispecific antibodies having specificity for ror1 and cd3
WO2022171892A1 (en) 2021-02-15 2022-08-18 Affibody Ab New her2-binding polypeptide
IL305301A (en) 2021-02-19 2023-10-01 Us Health Single domain antibodies neutralizing SARS CoV-2
WO2023052541A1 (en) 2021-09-30 2023-04-06 Imcheck Therapeutics Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
TW202405009A (zh) 2022-03-30 2024-02-01 瑞士商諾華公司 使用抗利尿鈉肽受體１（ｎｐｒ１）抗體治療障礙之方法
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
WO2024056668A1 (en) 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
WO2024074498A1 (en) 2022-10-04 2024-04-11 Imcheck Therapeutics Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4666884A (en) * 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
SE8505922D0 (sv) * 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
DE3879395T2 (de) * 1987-05-29 1993-06-24 Sagami Chem Res Fusionsprotein, enthaltend lymphotoxin.
GB8728856D0 (en) * 1987-12-10 1988-01-27 Bradwell A R Tumour-locating agents & method of locating tumours

Also Published As

Publication number Publication date
AU652124B2 (en) 1994-08-18
DE69010206D1 (de) 1994-07-28
DE69010206T2 (de) 1994-10-13
EP0486525A1 (en) 1992-05-27
WO1991001743A1 (en) 1991-02-21
SE509359C2 (sv) 1999-01-18
CA2064689C (en) 2002-04-30
ATE107514T1 (de) 1994-07-15
EP0486525B1 (en) 1994-06-22
CA2064689A1 (en) 1991-02-02
JP3477196B2 (ja) 2003-12-10
SE8902638D0 (sv) 1989-08-01
JPH04507242A (ja) 1992-12-17
AU6143990A (en) 1991-03-11

Similar Documents

Publication Publication Date Title
SE8902638L (sv) Stabiliserade protein- eller peptidkonjugat
DE3772521D1 (de) Insulinzubereitung fuer nicht-parenterale verabreichung.
DK0751781T3 (da) Anvendelse af monoklonale antistoffer eller oplöselige oligomere ligander til fremstillingen af et medikament til forebyggelse eller behandling af neoplastiske sygdomme
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
ZA943464B (en) Vascular endothelial growth factor 2
BR9206398A (pt) Peptídio, processo para promover a liberação de níveis de hormônio de crescimento em um animal, composição farmacêutica, processos para promover a liberação e elevação de níveis de hormônio de crescimento no sangue, para tratar nanismo pituitário hipotalâmico, osteoporose ou queimaduras, para promover a cicatrização de feridas, a recuperação de cirurgias ou recuperação de doenças debilitantes agudas/crônicas, para prevenir ou reduzir caquexia em pacientes com câncer, para promover o anabolismo e/ou evitar catabolismo em seres humanos, para aumentar o músculo em um animal e/ou diminuir a gordura do corpo, para melhorar o padrão de lipídios no soro em seres humanos, e para preparar compostos
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
ATE216402T1 (de) Opioid-konjugate mit endogenen trägerproteinen
CA2295199A1 (en) Method for treating vascular proliferative diseases with p27 and fusions thereof
EP0770680A3 (en) Lymphocyte-associated cell surface protein
RU97105374A (ru) Модифицированные белки
ATE337339T1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
EP0376251A3 (en) An anticoagulant substance obtained from urine
CA2154080A1 (en) Novel anticoagulant cofactor activity
ATE144149T1 (de) Therapeutisches verfahren zur behandlung von iddm
NZ332829A (en) Use of a polypeptide corresponding to a serine threonine kinase receptor, ALK-7 for neurological diseases
ATE111525T1 (de) Plasminogenaktivator-varianten und verfahren zu ihrer herstellung.
NO890174L (no) Rekombinante interleukin-1alfa-polypeptider.
ES2040765T3 (es) Procedimiento para preparar un agente para el tratamiento de enfermedades angiogenas o tumores.
AU2459188A (en) Anticoagulative protein pp4-x, and its preparation and use
DK0542869T3 (da) Vævsplasminogenaktivatorvarianter med nedsat udskillelse
EP0303538A3 (en) Protein with a vascular activity, derived from monocytes and their analogues, process for its use as a therapeutic agent and the preparation of antibodies
Krumwieh et al. Biological characterization of recombinant human erythropoietin

Legal Events

Date Code Title Description
NUG Patent has lapsed